Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on efficacy seem to support its use, there are potential cardiac toxicities which need to be considered, especially for women at lower risk of recurrence, or those at increased cardiovascular risk.

Trastuzumab containing regimens for early breast cancer / L. Moja, L. Tagliabue, S. Balduzzi, E. Parmelli, V. Pistotti, V. Guarneri, R. D'Amico. - In: COCHRANE DATABASE OF SYSTEMATIC REVIEWS. - ISSN 1469-493X. - 2012:4(2012 Apr), pp. CD006243.1-CD006243.85.

Trastuzumab containing regimens for early breast cancer

L. Moja;TAGLIABUE, LUDOVICA;
2012-04

Abstract

Approximately one-fifth of women who develop early breast cancer have HER2-positive tumours, which if untreated, have a worse prognosis than HER2-negative tumours. Trastuzumab is a selective treatment targeting the HER2 pathway. Although the results on efficacy seem to support its use, there are potential cardiac toxicities which need to be considered, especially for women at lower risk of recurrence, or those at increased cardiovascular risk.
Settore MED/06 - Oncologia Medica
Settore BIO/14 - Farmacologia
COCHRANE DATABASE OF SYSTEMATIC REVIEWS
Article (author)
File in questo prodotto:
File Dimensione Formato  
trastuzumab.pdf

non disponibili

902.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/206737
Citazioni
  • ???jsp.display-item.citation.pmc??? 178
  • Scopus 415
  • ???jsp.display-item.citation.isi??? 373
social impact